METAL CHELATE CONJUGATED MONOCLONAL ANTIBODIES FOR TUMOR DX & THERAPY

肿瘤 DX 金属螯合单克隆抗体

• 批准号: 3874413
• 负责人: O A GANSOW
• 金额: --
• 依托单位: DIVISION OF CANCER TREATMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3874413
• 关键词: alpha radiation; antileukemic agent; antitumor antibody; athymic mouse; beta radiation; chelating agents; chemical synthesis; cytolysis; disease /disorder model; drug design /synthesis /production; immunoconjugates; laboratory mouse; monoclonal antibody; mouse leukemia; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunotherapy; neoplasm /cancer radiodiagnosis; neoplasm /cancer radionuclide therapy; radionuclide imaging /scanning; radiopharmacology; viral leukemia; yttrium

Tumor-associated monoclonal antibodies are potential therapeutic agents as selective carriers of cytotoxic agents to malignant cells. We are testing this hypothesis in several animal model systems: one is a tumor virus induced leukemia of mice; another is human tumor xenographs in nude athymic mice. The cytocidal agents being employed are various radionuclides. Their relative efficacy when conjugated to monoclonal antibodies is being assayed and compared to that of monoclonal antibodies alone or conjugated to toxins. The several radionuclides chosen for study span the range of nuclidic properties available, thus Copper-67 represents a weak, short range, low energy beta emitter, Yttrium-90 is a long range, high energy beta emitter, Bismuth-212 is a short-lived, alpha emitter and Lead-212 provides both short and long range beta,emissions and the subsequent alpha emission of its Bismuth-212 daughter. The syntheses of the chelating agents required for linkage of these isotopes to antibody is now complete. The Bi-DOTA complex has been shown to be stable in an animal model system.

肿瘤相关的单克隆抗体是潜在的治疗剂 细胞毒性剂对恶性细胞的选择性载体。我们正在测试 在几种动物模型系统中的这一假设：一种是肿瘤病毒 诱发小鼠的白血病；另一个是裸露的人类肿瘤饰面 老鼠。 所使用的胞位剂是各种放射性核素。他们的 当共轭与单克隆抗体时，正在分析相对功效 并与单独的单克隆抗体或共轭相比 毒素。为研究选择的几种放射性核素跨越 可用的核素特性，因此铜-67代表弱，短 范围，低能Beta发射极，YTTrium-90是远距离的，高能量 Beta Emitter，Bismuth-212是短暂的Alpha Emitter和Lead-212 提供短距离和远距离Beta，排放和随后的Alpha 发射其Bismuth-212女儿。螯合剂的合成 这些同位素与抗体的连锁需要已完成。 BI-DOTA复合物已显示在动物模型系统中是稳定的。